Elutia

Yahoo Finance • 16 days ago

Elutia Inc (ELUT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Moves Amid ...

This article first appeared on GuruFocus. Revenue: $3.3 million for Q4 2025, up 16% from $2.8 million in Q4 2024. Gross Margin: Adjusted gross margin of 66.8% for Q4 2025, up from 56.5% in Q4 2024. Net Loss from Continuing Operations: $6.... Full story

Yahoo Finance • 5 months ago

Elutia outlines plan for NXT-41x launch in $1.5B breast reconstruction market following $88M asset sale

Earnings Call Insights: Elutia Inc. (ELUT) Q3 2025 MANAGEMENT VIEW * CEO C. Mills emphasized Elutia's mission of "humanizing medicine so that patients can thrive without compromise," spotlighting the company's strategic focus on breast... Full story

Yahoo Finance • 5 months ago

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21

GAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at th... Full story

Yahoo Finance • 6 months ago

Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors

Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug... Full story

Yahoo Finance • 6 months ago

Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million

- Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market - GAITHERSBURG, Md., Oct. 01, 2025 (GLOBE NEWSWIRE) -- E... Full story

Yahoo Finance • 7 months ago

Sector Update: Health Care Stocks Rise in Afternoon Trading

Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index and the Health Care Selec PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 7 months ago

Boston Scientific buys Elutia's bioenvelope business for $88 million

* Elutia (NASDAQ:ELUT [https://seekingalpha.com/symbol/ELUT]) said on Tuesday that it has entered into a definitive agreement to sell its EluPro and CanGaroo bioenvelopes, designed to protect patients receiving implantable medical device... Full story

Yahoo Finance • 7 months ago

Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million

- Transaction affirms the strength of Elutia’s proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - - Company to provide update at the H.C. Wainwright 27th Annual Global Investment C... Full story

Yahoo Finance • 7 months ago

Elutia targets $20M EluPro revenue run rate and NXT-41 launch in H2 2026 while advancing hospital penetration

Earnings Call Insights: Elutia Inc. (ELUT) Q2 2025 MANAGEMENT VIEW * CEO C. Randal Mills highlighted the ongoing commercial success of EluPro, reporting "49% sequential growth this quarter over last quarter built on the back of 7 natio... Full story

Yahoo Finance • 7 months ago

Earnings call transcript: Aleutia's Q2 2025 results show mixed performance

Aleutia reported its Q2 2025 earnings, revealing a mixed performance with a loss per share of $0.26, missing the forecasted $0.19 loss. Revenue for the quarter came in at $6.3 million, falling short of the $7.8 million expectation. Despite... Full story

Yahoo Finance • 7 months ago

Elutia GAAP EPS of -$0.23, revenue of $6.3M

* Elutia press release [https://seekingalpha.com/pr/20201874-elutia-delivers-robust-growth-on-the-strength-of-elupro-market-adoption] (NASDAQ:ELUT [https://seekingalpha.com/symbol/ELUT]): Q2 GAAP EPS of -$0.23. * Revenue of $6.3M. MOR... Full story

Yahoo Finance • 7 months ago

Elutia earnings missed by $0.07, revenue fell short of estimates

Investing.com - Elutia (NASDAQ: ELUT) reported second quarter EPS of $-0.260, $0.07 worse than the analyst estimate of $-0.190. Revenue for the quarter came in at $6.26M versus the consensus estimate of $7.8M. Elutia’s stock price closed... Full story

Yahoo Finance • 8 months ago

Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medical Device Innovator Award

GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Michelle LeRoux Williams, Chief Scientific Officer, h... Full story

Yahoo Finance • 8 months ago

[Latest] Global Cardiac Tissue Engineering Market Size/Share Worth USD 2,943.92 Million by 2034 at a 16.65% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cardiac Tissue Engineering Market size & share revenue was valued at approximately U... Full story

Yahoo Finance • 11 months ago

Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29

SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia’s Chief Scientific Officer, will... Full story

Yahoo Finance • 12 months ago

Elutia to Participate in Upcoming Investor Conferences

SILVER SPRING, Md., April 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguso... Full story

Yahoo Finance • last year

Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™

Seventh GPO Agreement Signed Since EluPro’s Launch SILVER SPRING, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced that it has entere... Full story

Yahoo Finance • last year

Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope

— Rigorous testing demonstrates robust antimicrobial performance against bacterial strains relevant to cardiac implanted electronic device (CIED) infections — SILVER SPRING, Md., March 25, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: E... Full story

Yahoo Finance • last year

Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out

– Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization – SILVER SPRING, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in d... Full story

Yahoo Finance • last year

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and full year 2024 fi... Full story